# ACM Research, Inc.: financial statements, quarterly ACMR · Nasdaq · CIK 1680062 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/acmr.md) · [Financials](/companies/acmr/financials.md) · [Filings](/companies/acmr/filings.md) · [Insiders](/companies/acmr/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/acmr/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [169](/filings/0001680062-24-000020.md) | [170 d](/filings/0001628280-26-013231.md) | [152](/filings/0001680062-25-000010.md) | [202](/filings/0001680062-25-000017.md) | [204](/filings/0001628280-25-050152.md) | [223 d](/filings/0001628280-26-013231.md) | [172](/filings/0001628280-26-032842.md) | [215](/filings/0001628280-26-054832.md) | [269](/filings/0001628280-25-050152.md) | [244 d](/filings/0001628280-26-013231.md) | [231](/filings/0001628280-26-032842.md) | [293](/filings/0001628280-26-054832.md) | | Cost of revenue | $m | [80.1](/filings/0001680062-24-000020.md) | [91.2 d](/filings/0001628280-26-013231.md) | [73.1](/filings/0001680062-25-000010.md) | [106](/filings/0001680062-25-000017.md) | [99.1](/filings/0001628280-25-050152.md) | [113 d](/filings/0001628280-26-013231.md) | [89.8](/filings/0001628280-26-032842.md) | [111](/filings/0001628280-26-054832.md) | [156](/filings/0001628280-25-050152.md) | [145 d](/filings/0001628280-26-013231.md) | [124](/filings/0001628280-26-032842.md) | [158](/filings/0001628280-26-054832.md) | | Gross profit | $m | [88.5](/filings/0001680062-24-000020.md) | [79.1 d](/filings/0001628280-26-013231.md) | [79.1](/filings/0001680062-25-000010.md) | [96.8](/filings/0001680062-25-000017.md) | [105](/filings/0001628280-25-050152.md) | [111 d](/filings/0001628280-26-013231.md) | [82.6](/filings/0001628280-26-032842.md) | [104](/filings/0001628280-26-054832.md) | [113](/filings/0001628280-25-050152.md) | [99.9 d](/filings/0001628280-26-013231.md) | [107](/filings/0001628280-26-032842.md) | [135](/filings/0001628280-26-054832.md) | | Research and development | $m | [26.2](/filings/0001680062-24-000020.md) | [32.5 d](/filings/0001628280-26-013231.md) | [23.9](/filings/0001680062-25-000010.md) | [26.0](/filings/0001680062-25-000017.md) | [27.8](/filings/0001628280-25-050152.md) | [27.8 d](/filings/0001628280-26-013231.md) | [27.5](/filings/0001628280-26-032842.md) | [33.8](/filings/0001628280-26-054832.md) | [39.7](/filings/0001628280-25-050152.md) | [44.0 d](/filings/0001628280-26-013231.md) | [36.5](/filings/0001628280-26-032842.md) | [42.3](/filings/0001628280-26-054832.md) | | Operating income | $m | [33.2](/filings/0001680062-24-000020.md) | [23.4 d](/filings/0001628280-26-013231.md) | [25.2](/filings/0001680062-25-000010.md) | [37.6](/filings/0001680062-25-000017.md) | [44.2](/filings/0001628280-25-050152.md) | [44.0 d](/filings/0001628280-26-013231.md) | [25.8](/filings/0001628280-26-032842.md) | [31.7](/filings/0001628280-26-054832.md) | [28.9](/filings/0001628280-25-050152.md) | [23.0 d](/filings/0001628280-26-013231.md) | [36.2](/filings/0001628280-26-032842.md) | [49.7](/filings/0001628280-26-054832.md) | | Interest expense | $m | [0.6](/filings/0001680062-23-000021.md) | [0.7 d](/filings/0001680062-24-000008.md) | [0.8](/filings/0001680062-24-000012.md) | [0.9](/filings/0001680062-25-000017.md) | [1.2](/filings/0001628280-25-050152.md) | [1.2 d](/filings/0001628280-26-013231.md) | [1.6](/filings/0001628280-26-032842.md) | [1.8](/filings/0001628280-26-054832.md) | [1.9](/filings/0001628280-25-050152.md) | [1.8 d](/filings/0001628280-26-013231.md) | [1.9](/filings/0001628280-26-032842.md) | [2.1](/filings/0001628280-26-054832.md) | | Income tax | $m | [0.7](/filings/0001680062-24-000020.md) | [8.1 d](/filings/0001628280-26-013231.md) | [4.4](/filings/0001680062-25-000010.md) | [9.3](/filings/0001680062-25-000017.md) | [4.0](/filings/0001628280-25-050152.md) | [17.3 d](/filings/0001628280-26-013231.md) | [2.2](/filings/0001628280-26-032842.md) | [1.9](/filings/0001628280-26-054832.md) | [2.7](/filings/0001628280-25-050152.md) | [6.6 d](/filings/0001628280-26-013231.md) | [3.8](/filings/0001628280-26-032842.md) | [13.5](/filings/0001628280-26-054832.md) | | Net income | $m | [25.7](/filings/0001680062-24-000020.md) | [17.7 d](/filings/0001628280-26-013231.md) | [17.4](/filings/0001680062-25-000010.md) | [24.2](/filings/0001680062-25-000017.md) | [30.9](/filings/0001628280-25-050152.md) | [31.1 d](/filings/0001628280-26-013231.md) | [20.4](/filings/0001628280-26-032842.md) | [29.8](/filings/0001628280-26-054832.md) | [35.9](/filings/0001628280-25-050152.md) | [8.0 d](/filings/0001628280-26-013231.md) | [17.3](/filings/0001628280-26-032842.md) | [89.0](/filings/0001628280-26-054832.md) | | Diluted EPS | $ per share | [0.39](/filings/0001680062-24-000020.md) | not reported | [0.26](/filings/0001680062-25-000010.md) | [0.35](/filings/0001680062-25-000017.md) | [0.45](/filings/0001628280-25-050152.md) | not reported | [0.30](/filings/0001628280-26-032842.md) | [0.44](/filings/0001628280-26-054832.md) | [0.52](/filings/0001628280-25-050152.md) | not reported | [0.24](/filings/0001628280-26-032842.md) | [1.23](/filings/0001628280-26-054832.md) | | Basic EPS | $ per share | [0.43](/filings/0001680062-24-000020.md) | not reported | [0.28](/filings/0001680062-25-000010.md) | [0.39](/filings/0001680062-25-000017.md) | [0.49](/filings/0001628280-25-050152.md) | not reported | [0.32](/filings/0001628280-26-032842.md) | [0.47](/filings/0001628280-26-054832.md) | [0.56](/filings/0001628280-25-050152.md) | not reported | [0.26](/filings/0001628280-26-032842.md) | [1.31](/filings/0001628280-26-054832.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [207](/filings/0001680062-24-000020.md) | [182](/filings/0001628280-26-013231.md) | [211](/filings/0001680062-25-000010.md) | [324](/filings/0001680062-25-000017.md) | [333](/filings/0001628280-25-050152.md) | [407](/filings/0001628280-26-013231.md) | [457](/filings/0001628280-26-032842.md) | [442](/filings/0001628280-26-054832.md) | [1,059](/filings/0001628280-25-050152.md) | [757](/filings/0001628280-26-054832.md) | [872](/filings/0001628280-26-032842.md) | [969](/filings/0001628280-26-054832.md) | | Current assets | $m | [1,116](/filings/0001680062-23-000021.md) | [1,176](/filings/0001680062-25-000003.md) | [1,229](/filings/0001680062-24-000012.md) | [1,343](/filings/0001680062-24-000016.md) | [1,445](/filings/0001680062-24-000020.md) | [1,483](/filings/0001628280-26-013231.md) | [1,548](/filings/0001680062-25-000010.md) | [1,646](/filings/0001680062-25-000017.md) | [2,358](/filings/0001628280-25-050152.md) | [2,437](/filings/0001628280-26-054832.md) | [2,619](/filings/0001628280-26-032842.md) | [2,875](/filings/0001628280-26-054832.md) | | Total assets | $m | [1,410](/filings/0001680062-23-000021.md) | [1,491](/filings/0001680062-25-000003.md) | [1,557](/filings/0001680062-24-000012.md) | [1,668](/filings/0001680062-24-000016.md) | [1,794](/filings/0001680062-24-000020.md) | [1,856](/filings/0001628280-26-013231.md) | [1,934](/filings/0001680062-25-000010.md) | [2,040](/filings/0001680062-25-000017.md) | [2,771](/filings/0001628280-25-050152.md) | [2,872](/filings/0001628280-26-054832.md) | [3,066](/filings/0001628280-26-032842.md) | [3,399](/filings/0001628280-26-054832.md) | | Current liabilities | $m | [482](/filings/0001680062-23-000021.md) | [501](/filings/0001680062-25-000003.md) | [533](/filings/0001680062-24-000012.md) | [586](/filings/0001680062-24-000016.md) | [610](/filings/0001680062-24-000020.md) | [641](/filings/0001628280-26-013231.md) | [629](/filings/0001680062-25-000010.md) | [671](/filings/0001680062-25-000017.md) | [678](/filings/0001628280-25-050152.md) | [746](/filings/0001628280-26-054832.md) | [746](/filings/0001628280-26-032842.md) | [786](/filings/0001628280-26-054832.md) | | Total liabilities | $m | [532](/filings/0001680062-23-000021.md) | [565](/filings/0001680062-25-000003.md) | [596](/filings/0001680062-24-000012.md) | [666](/filings/0001680062-24-000016.md) | [725](/filings/0001680062-24-000020.md) | [760](/filings/0001628280-26-013231.md) | [778](/filings/0001680062-25-000010.md) | [848](/filings/0001680062-25-000017.md) | [885](/filings/0001628280-25-050152.md) | [942](/filings/0001628280-26-054832.md) | [982](/filings/0001628280-26-032842.md) | [994](/filings/0001628280-26-054832.md) | | Long-term debt | $m | [39.8](/filings/0001680062-23-000021.md) | [54.0](/filings/0001680062-25-000003.md) | [53.4](/filings/0001680062-24-000012.md) | [70.8](/filings/0001680062-24-000016.md) | [106](/filings/0001680062-24-000020.md) | [106](/filings/0001628280-26-013231.md) | [135](/filings/0001680062-25-000010.md) | [163](/filings/0001680062-25-000017.md) | [193](/filings/0001628280-25-050152.md) | [179](/filings/0001628280-26-054832.md) | [221](/filings/0001628280-26-032842.md) | [193](/filings/0001628280-26-054832.md) | | Current portion of debt | $m | [6.7](/filings/0001680062-23-000021.md) | [6.8](/filings/0001680062-25-000003.md) | [6.5](/filings/0001680062-24-000012.md) | [19.7](/filings/0001680062-24-000016.md) | [30.7](/filings/0001680062-24-000020.md) | [44.5](/filings/0001628280-26-013231.md) | [67.9](/filings/0001680062-25-000010.md) | [62.1](/filings/0001680062-25-000017.md) | [48.6](/filings/0001628280-25-050152.md) | [35.1](/filings/0001628280-26-054832.md) | [13.3](/filings/0001628280-26-032842.md) | [40.8](/filings/0001628280-26-054832.md) | | Short-term borrowings | $m | [33.9](/filings/0001680062-23-000021.md) | [31.3](/filings/0001680062-25-000003.md) | [54.7](/filings/0001680062-24-000012.md) | [54.4](/filings/0001680062-24-000016.md) | [33.8](/filings/0001680062-24-000020.md) | [32.8](/filings/0001628280-26-013231.md) | [25.0](/filings/0001680062-25-000010.md) | [53.0](/filings/0001680062-25-000017.md) | [45.0](/filings/0001628280-25-050152.md) | [74.0](/filings/0001628280-26-054832.md) | [94.0](/filings/0001628280-26-032842.md) | [107](/filings/0001628280-26-054832.md) | | Shareholders' equity | $m | [729](/filings/0001680062-23-000021.md) | [767](/filings/0001680062-25-000003.md) | [796](/filings/0001680062-24-000012.md) | [833](/filings/0001680062-24-000016.md) | [888](/filings/0001680062-24-000020.md) | [905](/filings/0001628280-26-013231.md) | [949](/filings/0001680062-25-000010.md) | [986](/filings/0001680062-25-000017.md) | [1,433](/filings/0001628280-25-050152.md) | [1,464](/filings/0001628280-26-054832.md) | [1,582](/filings/0001628280-26-032842.md) | [1,860](/filings/0001628280-26-054832.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Short-term borrowings: us-gaap:ShortTermBorrowings - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [(17.8) d](/filings/0001680062-24-000020.md) | [(38.4) d](/filings/0001628280-26-013231.md) | [(9.6)](/filings/0001680062-25-000010.md) | [61.6 d](/filings/0001680062-25-000017.md) | [11.9 d](/filings/0001628280-25-050152.md) | [88.6 d](/filings/0001628280-26-013231.md) | [5.3](/filings/0001628280-26-032842.md) | [(44.9) d](/filings/0001628280-26-054832.md) | [(4.6) d](/filings/0001628280-25-050152.md) | [33.9 d](/filings/0001628280-26-013231.md) | [(29.5)](/filings/0001628280-26-032842.md) | [(6.4) d](/filings/0001628280-26-054832.md) | | Capital expenditure | $m | [27.9 d](/filings/0001680062-24-000020.md) | [12.3 d](/filings/0001628280-26-013231.md) | [25.4](/filings/0001680062-25-000010.md) | [13.1 d](/filings/0001680062-25-000017.md) | [32.5 d](/filings/0001628280-25-050152.md) | [11.4 d](/filings/0001628280-26-013231.md) | [16.7](/filings/0001628280-26-032842.md) | [14.7 d](/filings/0001628280-26-054832.md) | [11.0 d](/filings/0001628280-25-050152.md) | [13.8 d](/filings/0001628280-26-013231.md) | [22.2](/filings/0001628280-26-032842.md) | [65.1 d](/filings/0001628280-26-054832.md) | | Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Share repurchases: not reported ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [65.6](/filings/0001680062-23-000021.md) | [65.1](/filings/0001680062-24-000012.md) | [64.9](/filings/0001680062-24-000016.md) | [65.5](/filings/0001680062-24-000020.md) | [66.2](/filings/0001680062-25-000010.md) | [67.1](/filings/0001680062-25-000017.md) | [66.7](/filings/0001628280-25-050152.md) | [67.0](/filings/0001628280-26-032842.md) | [67.5](/filings/0001628280-26-054832.md) | [68.4](/filings/0001628280-25-050152.md) | [69.8](/filings/0001628280-26-032842.md) | [71.8](/filings/0001628280-26-054832.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 14,176,690 at 2019-03-08, from the cover of the [10-K filed 2019-03-14](/filings/0001654954-19-002737.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.